암젠 (AMGN) 주가 전망: 목표주가, 배당, 최신 뉴스

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co. , Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.

The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.는 전 세계적으로 인체용 치료제를 발굴·개발·제조·공급하는 기업입니다. 주요 제품으로는 류머티스 관절염·판상 건선·건선성 관절염 치료제 Enbrel, 판상 건선·건선성 관절염·베체트병 관련 구강궤양 치료제 Otezla, 폐경 후 여성의 골다공증 치료제 Prolia, 골격계 관련 사건 예방을 위한 XGEVA, 심근경색·뇌졸중·관상동맥 재관류 위험을 낮추는 Repatha, 면역혈소판감소증 치료제 Nplate, 재발성 또는 불응성 다발성 골수종 치료제 KYPROLIS, 적혈구 수 감소 및 빈혈 치료제 Aranesp, 폐경 후 여성 골다공증 치료제 EVENITY, 야생형 RAS 전이성 대장암 치료제 Vectibix, 급성 림프구성 백혈병 치료제 BLINCYTO, 갑상선 안병증 치료제 TEPEZZA, 만성 불응성 통풍 치료제 KRYSTEXXA 등이 있습니다.

그 밖에도 PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA, VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, PROCYSBI 등 다양한 제품을 판매하고 있습니다.

Amgen은 의사 및 의원, 투석센터, 병원, 약국 등 의료 제공자를 고객으로 삼고 있으며 제약 도매 유통업자를 통해 제품을 공급합니다. 또한 TEZSPIRE의 개발·상업화를 위한 AstraZeneca plc, Aimovig의 개발·상업화를 위한 BEONE MEDICINES LTD., EVENITY의 개발·상업화를 위한 UCB, rocatinlimab 개발·상업화를 위한 Kyowa Kirin Co., Ltd., 종양학 제품 확장 및 개발을 위한 BeiGene, Ltd. 등과 협력 계약을 체결하고 있습니다. 회사는 1980년에 설립되었고 본사는 캘리포니아주 Thousand Oaks에 있습니다.

• 주소: One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States

• 전화번호: 805 447 1000

• 웹사이트: https://www.amgen.com

• 섹터: Healthcare

• 산업: Drug Manufacturers - General

• 직원 수: 31,500